Log In
Print
BCIQ
Print
Print this Print this
 

ASP-502D

  Manage Alerts
Collapse Summary General Information
Company Ascepion Pharmaceuticals Inc.
DescriptionOral tyrosine kinase receptor inhibitor
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today